Saturday 17 October 2026 Export YI’s income statement to Excel — free account

111, Inc. Sponsored ADR

111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024. In the quarter to March 2026, revenue fell 29.6%, EPS fell 200.0%, free cash flow fell 185.7% and total debt rose 82.5%, each against the same quarter a year earlier.

3.09 0.00 0.00%

Follow YI

Alert me

Market cap: $16.0M
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 5/9
Altman Z: 3.31
Beneish M: −3.28
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	9	—	—	—	—	—

Insider Ownership 42.13%

Capital & Financial Ratios $m

Market Cap 16.04

Revenue 1,651.50

Net Income (3.22)

Free Cash Flow (11.78)

Net Debt (20.15)

Current Ratio 1.08

Debt/Equity (0.34)

P/E ratio 0.00

Fwd P/E 0.00

P/S ratio 0.02

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 9.40%

Next Y EPS Growth —

Next Y revenue growth 33.58%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 45.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	95	71	87	57
Receivables	76	57	37	27
Inventory	200	190	143	147
Other	—	—	—	—
	413	363	304	270

	2023	2024	2025	Q'26
Payables	224	236	183	176
ST’ Debt	48	22	27	37
Other	—	—	—	—
	387	321	279	249

Compound Annual Growth %

	10y	5y	3y
Sales	—	7.39%	(2.88%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	342	—	—	—	—
’25	486	448	422	440	1,795
’24	489	471	513	500	1,973
’23	538	480	502	585	2,105
’22	470	453	471	565	1,960
’21	396	468	519	566	1,950
’20	223	230	348	457	1,257

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	—	—	—	—
’25	16	(8)	5	4	17
’24	15	13	17	(8)	36
’23	(18)	(22)	5	(29)	(63)
’22	(11)	(4)	3	9	(3)
’21	(40)	(2)	(17)	(50)	(108)
’20	(16)	18	4	(24)	(18)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	—	—	—	—
’25	16	(8)	5	4	16
’24	15	13	17	(8)	34
’23	(18)	(22)	5	(29)	(64)
’22	(11)	(4)	3	9	(8)
’21	(40)	(2)	(17)	(50)	(118)
’20	(16)	18	4	(24)	(22)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.60)	—	—	—	—
’25	(0.20)	(0.40)	(0.20)	(0.20)	(1.00)
’24	(0.20)	(0.20)	(0.20)	(0.04)	(0.10)
’23	(0.60)	(1.00)	(1.60)	(3.40)	(6.60)
’22	(2.00)	(1.80)	(1.60)	(2.00)	(7.20)
’21	(2.80)	(3.00)	(4.80)	(2.20)	(12.60)
’20	(2.20)	(1.60)	(2.00)	(2.40)	(8.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	6.00	2.29	5.20	3.01	1.37	1.19	0.50	0.41	Analyst estimates 2026–2028 Powerpack
	High	—	—	16.83	10.80	8.70	45.88	4.00	3.48	1.85	11.35
People
People	Employees	—	1,117	1,350	1,932	2,189	2,114	1,657	1,520	1,238	1,063
	Revenue/emp, $m	0.00	0.13	0.19	0.29	0.57	0.92	1.18	1.39	1.59	1.69
Income, $m
Income, $m	Revenue	132	145	260	568	1,257	1,950	1,960	2,105	1,973	1,795
	Gross margin, %	9.09	9.46	5.84	4.18	4.46	5.00	6.21	5.68	5.76	5.76
	EBT	(55)	(38)	(56)	(72)	(72)	(97)	(55)	(50)	(3)	(3)
	EBT margin, %	(41.67)	(25.99)	(21.39)	(12.70)	(5.69)	(5.00)	(2.78)	(2.36)	(0.14)	(0.18)
	Net income	(55)	(38)	(56)	(72)	(72)	(97)	(55)	(50)	(3)	(3)
	Depreciation	2	2	2	2	2	4	6	3	2	2
Per share, $
Per share, $	Revenue	1.61	40.28	52.24	69.37	152.58	235.11	235.21	249.74	229.63	206.35
	Earnings	(0.38)	(10.47)	(11.10)	(8.80)	(8.40)	(12.60)	(7.20)	(6.60)	(0.10)	(1.00)
	Cash flow	(0.71)	(8.58)	(10.03)	(8.99)	(2.17)	(13.03)	(0.40)	(7.47)	4.19	1.96
	Capex	0.00	(0.29)	(0.43)	(0.43)	(0.48)	(1.18)	(0.53)	(0.14)	(0.23)	(0.07)
	Free cash flow	(0.71)	(8.86)	(10.46)	(9.42)	(2.65)	(14.21)	(0.93)	(7.61)	3.96	1.89
	Book value	1.92	(39.66)	35.79	13.58	7.56	(2.88)	(7.11)	(9.94)	(10.49)	(11.86)
	Shares, m	82	4	5	8	8	8	8	8	9	9
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.10	0.05	0.01	0.01	0.01	0.00	0.01
	P/B	0.00	0.00	0.14	0.50	0.92	0.00	0.00	0.00	0.00	0.00
	EV/Sales	0.00	0.00	0.00	(0.06)	(0.12)	(0.04)	(0.04)	(0.02)	(0.02)	(0.02)
	EV/FCF	0.00	0.00	0.00	0.43	5.86	0.62	3.30	0.40	(2.43)	(4.73)
Cash, $m
Cash, $m	Operating cash flow	(58)	(31)	(50)	(74)	(18)	(108)	(3)	(63)	36	17
	Capex	(1)	(1)	(2)	(4)	(4)	(10)	(4)	(1)	(2)	(1)
	Free cash flow	(58)	(32)	(52)	(77)	(22)	(118)	(8)	(64)	34	16
Balance, $m
Balance, $m	Working capital	105	80	173	102	190	105	74	27	42	24
	Total debt	—	—	—	14	35	41	26	48	22	27
	Net debt	(92)	(70)	(161)	(87)	(213)	(107)	(108)	(47)	(49)	(61)
	Shareholders’ equity	158	(143)	178	111	62	(24)	(59)	(84)	(90)	(103)
Returns, %
Returns, %	ROA	(36.72)	(25.19)	(32.49)	(31.46)	(20.13)	(21.96)	(12.12)	(11.78)	(2.17)	(2.73)
	ROIC	0.00	0.00	(213.47)	(180.08)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	51.65	31.08	(313.93)	(49.64)	(80.68)	(547.31)	145.42	77.35	10.20	9.82

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%	Compare
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
YI 111, Inc. Sponsored ADR	$16.0M	— (loss-making)	— (loss-making)	−29.61% (below 0%: shrinking)	n/m	−185.70% (below 0%: shrinking)	5.33%	(0.85%)
SNYRQ Synergy CHC Corp.	$1.3M	— (loss-making)	1.6×	−32.77% (below 0%: shrinking)	n/m	−148.51% (below 0%: shrinking)	72.29%	(10.32%)	Compare
Median of peers	$94.3M	—	20.9×	+6.73%	—	−40.53%	31.84%	(5.73%)

All 11 Medical Distribution stocks →

111, Inc. Sponsored ADR (YI) key facts

Concern: 111, Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.8 billion, down 9.00% from fiscal 2024.
111, Inc. Sponsored ADR (YI) is a Medical Distribution company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, YI traded at $3.09, a market capitalization of $16.0 million.
Return on equity was 9.82% and debt-to-equity -0.34.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.31 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.